ARCT•benzinga•
Wells Fargo Maintains Overweight on Arcturus Therapeutics, Lowers Price Target to $45
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 14, 2025 by benzinga